Daxiang Biotech has been recognized as the “Top Organoids-on-Chips Model Services in Asia 2026” by Life Sciences Review, highlighting the company’s innovation and contributions to advancing organoid-on-chip technologies for biomedical research, drug discovery, and preclinical development.

The recognition reflects Daxiang Biotech’s continued efforts to develop human-relevant models that provide more predictive insights for translational research and support the advancement of next-generation therapeutics.

According to Life Sciences Review, Daxiang Biotech was selected following an evaluation process conducted by its editorial board in collaboration with C-level executives and industry thought leaders. The recognition acknowledges the company’s technological capabilities, industry contributions, and reputation among customers and peers.

As part of this recognition, Life Sciences Review featured Daxiang Biotech in an in-depth article titled “Redefining Organoids-on-Chips as Decision-Grade Preclinical Infrastructure,” highlighting the company’s technology approach and vision for advancing human-relevant models.

Advancing Organoid-on-Chip Innovation for Human-Relevant Research

Daxiang Biotech develops integrated organoid-on-chip and microphysiological system (MPS) solutions by combining organoid biology, microfluidic engineering, artificial intelligence, and automation.

At the core of Daxiang’s technology platform is the Integrated Biomimetic Array Chip (IBAC®) framework, which integrates organoid models with AI-driven data analysis from the early stages of platform development. By defining imaging parameters, data structures, and analytical approaches alongside biological models, IBAC® is designed to improve data consistency, comparability, and translational value as research programs advance.

Yu Zhou, Founder and CEO of Daxiang Biotech, shared the company’s vision:

“In our vision, ‘organoids-on-chips + AI’ represents a transformative technology platform that can progressively replace animal models. We treat early in vitro data not as preliminary signals for later validation, but as credible evidence capable of advancing programs directly toward key regulatory milestones.”

Building Scalable Human-Relevant Platforms for Translational Research

Daxiang Biotech has established an integrated organoid-on-chip technology platform, including four IBAC® organoid-on-chip platforms, more than 50 organoid culture kits, and over 100 humanized physiological and pathological models.

These technologies support diverse applications, including disease modeling, drug screening, toxicity assessment, and translational research. Through standardized platform architectures and application-specific optimization, Daxiang aims to improve the reproducibility, scalability, and adoption of human-relevant models across biomedical research and pharmaceutical development.

Advancing the Future of Preclinical Research

Organoid-on-chip and microphysiological system technologies are emerging as important approaches for improving the predictability of preclinical research. By more closely reflecting human physiological conditions, these technologies offer new opportunities to enhance drug discovery efficiency, strengthen safety assessment, and accelerate translational development.

The recognition from Life Sciences Review represents an important milestone in Daxiang Biotech’s continued efforts to advance human-relevant models and expand the application of organoid-on-chip technologies.

Moving forward, Daxiang Biotech will continue developing standardized, scalable, and intelligent organoid-on-chip solutions and collaborating with researchers, pharmaceutical companies, and biotechnology partners worldwide to accelerate biomedical innovation.

About Daxiang Biotech

Daxiang Biotech is a biotechnology company specializing in organoid-on-chip, organoid technology, and microphysiological systems (MPS). Through the integration of biology, engineering, artificial intelligence, and automation, Daxiang develops human-relevant models and solutions to support drug discovery, disease modeling, toxicity assessment, and precision medicine.

https://www.lifesciencesreviewapac.com/edition/january-2026-78.html